Overview

Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
To study the safety and efficacy of anti-CD20 blockade with ofatumumab in the context of allogeneic HCT in CLL
Phase:
Phase 2
Details
Lead Sponsor:
Technische Universität Dresden
Collaborators:
University Hospital Dresden
University Hospital of Cologne
University Hospital Schleswig-Holstein
University Hospital Ulm
University of Schleswig-Holstein
Treatments:
Antibodies, Monoclonal
Ofatumumab